| Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial S Misawa, S Kuwabara, Y Sato, N Yamaguchi, K Nagashima, K Katayama, ... The Lancet Neurology 17 (6), 519-529, 2018 | 162 | 2018 |
| Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab K Masuda, H Shoji, K Nagashima, S Yamamoto, M Ishikawa, H Imazeki, ... BMC cancer 19, 1-10, 2019 | 116 | 2019 |
| Predictive power of a body shape index for development of diabetes, hypertension, and dyslipidemia in Japanese adults: a retrospective cohort study M Fujita, Y Sato, K Nagashima, S Takahashi, A Hata PLoS One 10 (6), e0128972, 2015 | 105 | 2015 |
| Study designs and statistical analyses for biomarker research M Gosho, K Nagashima, Y Sato Sensors 12 (7), 8966-8986, 2012 | 101 | 2012 |
| Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma K Ueshima, S Ogasawara, M Ikeda, Y Yasui, T Terashima, T Yamashita, ... Liver Cancer 9 (5), 583-595, 2020 | 83 | 2020 |
| Income-related inequalities in access to dental care services in Japan A Nishide, M Fujita, Y Sato, K Nagashima, S Takahashi, A Hata International journal of environmental research and public health 14 (5), 524, 2017 | 83 | 2017 |
| Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial S Misawa, Y Sato, K Katayama, K Nagashima, R Aoyagi, Y Sekiguchi, ... The Lancet Neurology 15 (11), 1129-1137, 2016 | 82 | 2016 |
| Prediction intervals for random-effects meta-analysis: a confidence distribution approach K Nagashima, H Noma, TA Furukawa Statistical Methods in Medical Research 28 (6), 1689–1702, 2019 | 76 | 2019 |
| A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy T Yanai, S Iwasa, H Hashimoto, F Ohyanagi, T Takiguchi, K Takeda, ... International journal of clinical oncology 23, 382-388, 2018 | 73 | 2018 |
| Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients K Tada, S Kitano, H Shoji, T Nishimura, Y Shimada, K Nagashima, K Aoki, ... Cancer immunology research 4 (7), 592-599, 2016 | 71 | 2016 |
| A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells H Fujie, K Niu, M Ohba, Y Tomioka, H Kitazawa, K Nagashima, T Ohrui, ... Inflammation 35, 1119-1131, 2012 | 68 | 2012 |
| The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure … N Kotooka, M Kitakaze, K Nagashima, M Asaka, Y Kinugasa, K Nochioka, ... Heart and vessels 33, 866-876, 2018 | 62 | 2018 |
| Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E) S Yamamoto, K Kato, H Daiko, T Kojima, H Hara, T Abe, Y Tsubosa, ... Future Oncology 16 (19), 1351-1357, 2020 | 53 | 2020 |
| Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer M Aoki, H Shoji, K Nagashima, H Imazeki, T Miyamoto, H Hirano, ... ESMO open 4 (3), e000488, 2019 | 48 | 2019 |
| Statistical Methods in the Journal — An Update Y Sato, M Gosho, K Nagashima, S Takahashi, JH Ware, NM Laird New England Journal of Medicine 376 (11), 1086-1087, 2017 | 48 | 2017 |
| Income related inequality of health care access in Japan: a retrospective cohort study M Fujita, Y Sato, K Nagashima, S Takahashi, A Hata PloS one 11 (3), e0151690, 2016 | 47 | 2016 |
| A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine-and platinum … T Shirakawa, K Kato, K Nagashima, A Nishikawa, R Sawada, ... Cancer chemotherapy and pharmacology 74, 1207-1215, 2014 | 44 | 2014 |
| Information criteria for Firth’s penalized partial likelihood approach in Cox regression models K Nagashima, Y Sato Statistics in Medicine 36 (21), 3422–3436, 2017 | 41 | 2017 |
| Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study). H Hara, H Shoji, D Takahari, T Esaki, N Machida, K Nagashima, K Aoki, ... Journal of Clinical Oncology 37 (4_suppl), 129-129, 2019 | 40 | 2019 |
| The quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcome after chemotherapy for patients with early-stage breast cancer T Iwase, T Sangai, T Nagashima, M Sakakibara, H Fujimoto, Y Sawabe, ... Cancer Research 78 (4 Supplement), P1-07-23, 2018 | 40 | 2018 |
Kazufumi Honda国立がん研究センター研究所ユニット長Verified email at ncc.go.jp
